Dual GIP/GLP-1 receptor agonist therapy offering clinically superior weight reduction — administered under physician supervision with personalized dosing and comprehensive metabolic monitoring.
Tirzepatide is a next-generation, physician-prescribed medication that activates both GIP and GLP-1 receptors — two key hormones that regulate appetite, blood sugar, and metabolism. By targeting both pathways at once, it produces some of the strongest weight loss results seen in clinical research, often exceeding 20% of body weight in qualifying patients. Treatment is delivered as a once-weekly self-injection, with dosing carefully titrated by your physician to balance effectiveness and tolerability. Regular check-ins and lab monitoring ensure safe, sustainable progress. Most patients see meaningful changes within the first three months, with optimal results developing over six to twelve months.
Tirzepatide activates both GIP and GLP-1 receptors simultaneously, delivering a synergistic effect on appetite, blood sugar, and metabolic rate. In clinical trials it has achieved average weight reductions of 20%+ in some cohorts. Dosing is carefully titrated by your physician based on response and tolerance.
Tirzepatide is generally appropriate for adults with a BMI of 27 or higher, type 2 diabetes, metabolic syndrome, or those struggling to lose weight despite lifestyle efforts. A consultation determines eligibility.
Tirzepatide targets both the GIP and GLP-1 receptors, while semaglutide targets only GLP-1. The dual-receptor action often produces greater appetite suppression and faster weight loss.
Mild nausea, fatigue, or gastrointestinal symptoms are common early on, especially during dose increases. Most side effects resolve within a few weeks as the body adjusts.
Most patients use tirzepatide for 6 to 12 months to reach their target weight, with a maintenance phase to support long-term results. Your physician will guide the plan.
Schedule your consultation with Dr. Parvataneni today.